I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Steven Jones, MD
Ciccarone Center Research
View by Topic
- Antiplatelet Therapy
- ASCVD (Atherosclerotic Cardiovascular Disease)
- Blood Pressure
- Cardiac CT
- Cardiovascular Risk Assessment
- Carotid Atherosclerosis
- Cerebrovascular Disease / Stroke / Cognitive Function
- Cholesterol / Lipids / Statins
- Cigarette Smoking
- Diabetes & Metabolic Syndrome
- Diet & Weight
- Disparities in Care
- Emotional Health
- Endothelial Function
- Erectile Dysfunction
- Exercise and Physical Fitness
- Family History of CVD
- Gender / Cardiovascular Disease in Women
- Heart Failure
- Heart Rate
- Markers of Thrombosis, Myocardial Injury, Wall Stress
- Mobile Health
- Nutrition, Vitamins, Supplements
- PVD – Peripheral Vascular Disease
- Quality of Care
- Renal Disease
- Rheumatoid Arthritis & Collagen Vascular Diseases
- Sleep Disorders
- Stem Cells
- Subclinical Atherosclerosis
- Vascular Imaging
- Vascular Stiffness
View by Journal
- American Heart Journal
- American Journal of Cardiology
- American Journal of Epidemiology
- American Journal of Hypertension
- Annals of Internal Medicine
- Arteriosclerosis, Thrombosis & Vascular Biology
- British Medical Journal
- Clinical Cardiology
- Diabetes Care
- European Heart Journal
- European Journal of Preventive Cardiology
- International Journal of Cardiology
- Journal of Hypertension
- Journal of the American College of Cardiology
- Journal of the American Heart Association
- Journal of the American Medical Association
- Mayo Clinic Proceedings
- New England Journal of Medicine
- PLoS One
View by Year
- Meet the Authors
This study shifts the focus from prediction of events to detection of disease in the effort to improve personalized decision-making and outcomes. It also discusses innovative future strategies for risk estimation and treatment allocation in preventive cardiology.Published in: American Journal of CardiologyRead on Pubmed
Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.CAC scoring can help match statin therapy to absolute atherosclerotic CVD risk.Published in: CirculationRead on Pubmed
Unhealthy lifestyle habits are a major contributor to coronary artery disease (CAD). The purpose of the study was to investigate the associations of smoking, weight maintenance, physical activity, and Mediterranean-style diet with coronary calcium, cardiovascular events, and mortality. We discovered that, over the course of nearly 8 years, a combination of regular exercise, healthy diet, smoking avoidance, and weight maintenance contributed to lower coronary calcium incidence, slower calcium progression, and lower all-cause mortality.Published in: American Journal of EpidemiologyRead on Pubmed
Early in 2012, a debate over the merits of statin therapy in primary prevention was published in the Wall Street Journal. The statin opponent claimed that statins should only be used in secondary prevention and never in any primary-prevention patients at risk for cardiovascular events. In this evidence-based rebuttal to those claims, we review the evidence supporting the efficacy of statin therapy in primary prevention. Cardiovascular risk is a continuum in which those at an elevated risk of events stand to benefit from early initiation of therapy. Statins should not be reserved until after a patient suffers the catastrophic consequences of atherosclerosis. Contrary to the assertions of the statin opponent, this principle has been demonstrated through reductions in heart attacks, strokes, and mortality in numerous randomized controlled primary-prevention statin trials. In selected at-risk individuals, the combination of pharmacotherapy and lifestyle changes is more effective than either alone. Future investigation in prevention should focus on improving our ability to identify these at-risk individuals.Published in: Clinical CardiologyRead on Pubmed
Coronary artery calcium progression: an important clinical measurement? A review of published reports.Baseline CAC accurately identifies coronary atherosclerosis and improves prediction of future cardiac events. However, whether knowledge of progression of CAC scores over time further improves risk prediction is unclear. We conducted a comprehensive review of published reports on CAC progression and found that CAC progression correlates with worsening atherosclerosis and may facilitate prediction of future cardiac events. These findings support the notion that slowing CAC progression with therapeutic interventions might provide prognostic benefit. However, despite promising early data, such interventions (most notably with statin therapy) have not been shown to slow the progression of CAC in any randomized controlled trial to date, outside of post hoc subgroup analyses. Thus, routine quantification of CAC progression cannot currently be recommended in clinical practice.Published in: Journal of the American College of CardiologyRead on Pubmed
Response to letter by Dr. Lin regarding article, “HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative.
Novel biomarkers and risk factors.
Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring cohort studies.
This study found that smaller, denser HDL3-C levels are primarily responsible for the inverse association between HDL-C and incident CHD in this diverse group of primary prevention subjects.
High-density lipoprotein subfractions: current views and clinical practice applications.
Metabolomic analysis of pressure-overloaded and infarcted mouse hearts.
These findings reveal extensive metabolic remodeling common to both hypertrophic and failing hearts that are indicative of extracellular matrix remodeling, insulin resistance and perturbations in amino acid, and lipid and nucleotide metabolism.
HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The Lipoprotein Investigators Collaborative.
In secondary prevention, increased risk for long-term hard clinical events is associated with low HDL3-C, but not HDL2-C or HDL-C, highlighting the potential value of subclassifying HDL-C.
2013 American cholesterol treatment guideline: what was done well and what could be done better.
This article critically appraises the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. The guideline succeeds in prioritizing statin therapy, expanding focus to atherosclerotic cardiovascular disease including stroke, and in emphasizing absolute cardiovascular risk to determine statin eligibility.
- Journal: Journal of the American College of Cardiology
- Year: 2014
- Topic: ASCVD (Atherosclerotic Cardiovascular Disease), Cholesterol / Lipids / Statins, Cardiovascular Risk Assessment
- Read more articles by: Roger S. Blumenthal, MD, Michael Blaha, MD, MPH, Erin Michos, MD, MHS, Seth Martin, MD, MHS, Steven Jones, MD
Letter by Jones et al regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.”
Usefulness of coronary and carotid imaging rather than traditional atherosclerotic risk factors to identify firefighters at increased risk for cardiovascular disease.
Early detection and integration of imaging with traditional risk assessment will be important in preventing premature death and disability among firefighters.
Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B).
The narrowing sex differential in CVD risk after midlife is mirrored by a higher total atherogenic lipoprotein cholesterol burden in women and a closer approximation of the less favorable density phenotype characteristic of men.
- Journal: Journal of the American Heart Association
- Year: 2014
- Topic: Cholesterol / Lipids / Statins, Gender / Cardiovascular Disease in Women
- Read more articles by: Gary Gerstenblith, MD, Roger S. Blumenthal, MD, Michael Blaha, MD, MPH, Erin Michos, MD, MHS, Khurram Nasir, MD, MPH, Seth Martin, MD, MHS, Steven Jones, MD